Tweetovi

Blokirali ste korisnika/cu @JorgeCondeBio

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @JorgeCondeBio

  1. Prikvačeni tweet
    2. pro 2019.

    With its ability to store information, replicate & evolve, biology is one of the most advanced technologies on earth. And now biology is becoming programmable. My take on what is powering our ability to read, write + execute programs in biology👇

    Poništi
  2. proslijedio/la je Tweet
    1. velj

    Accurate early detection blood test for cancer is going to be one of the most fundamental breakthroughs of our generation. Within a few years, we will detect cancer at the earliest points when it can be cured:

    Prikaži ovu nit
    Poništi
  3. 31. sij

    “Not Spicy = Not As Good” is a hill I’m willing to die on.

    Poništi
  4. 30. sij

    (and dad to a Spider-Verse Spider-Man)

    Poništi
  5. 26. sij

    “Don’t ask yourself what the world needs. Ask yourself what makes you come alive, and go do that, because what the world needs is people who have come alive.” — Howard Thurman (h/t )

    Poništi
  6. proslijedio/la je Tweet
    24. sij

    "It's easier to hold your principles 100 percent of the time than it is to hold them 98 percent of the time." -- Clayton Christensen, giant of enterprise, RIP

    Poništi
  7. proslijedio/la je Tweet
    23. sij

    5-year predictions 1. Active learning in biology - confluence of design (ML), build (large-scale dna synth/edit), and test (multiplexed assays) allows massive scale for exploring new function. Will require programmatic ways to explore that space. Expmnts no longer limiting. [1/n]

    Prikaži ovu nit
    Poništi
  8. 19. sij

    Should tech stick to tech; biotech to biotech? It’s hard to stay in your lane when roads merge. Some things are best for traditional tech/biotech; others, bio’s sweet spot. And tech, biotech + bio will work together to bridge from the old world + build the new. See you at !

    Prikaži ovu nit
    Poništi
  9. 19. sij

    Silicon Valley, ’s birthplace, is an important hub for both traditional biotech + next-gen bio companies. And a thriving ecosystem of seed, early- + late-stage bio investors has emerged. Like bio founders, these investors are multidisciplinary too.

    Prikaži ovu nit
    Poništi
  10. 19. sij

    ‘Reimbursement risk’ (aka value proposition risk) is changing too. As programmable medicines become more sophisticated, they offer potential cures—saving lives + avoiding downstream costs. We need new models to fairly distribute costs + benefits over many years.

    Prikaži ovu nit
    Poništi
  11. 19. sij

    ‘Regulatory risk’ (aka science risk) is changing as engineered bio pursues applications where iteration can reduce risk: ie optimize genome editors to repair known disease-causing errors; 1st clinical applications ex vivo (outside of body) that can be QC’d before they’re infused.

    Prikaži ovu nit
    Poništi
  12. 19. sij

    Bio companies are a hybrid between traditional tech + biotech. They merge siloed disciplines—and build cultures of relentless iteration + continuous improvement. Entrepreneurs unhappy w/ status quo seek to remake the entire industry (ie ). Naturally, skeptics abound.

    Prikaži ovu nit
    Poništi
  13. 19. sij

    We’re in a bio revolution. Innovation cycles are accelerating + compounding. Advances (ie DNA seq, CRISPR) rapidly adopted. Engineered bio creates generations that build on each other, like versions of software. Modular components can be remixed + reused (ie CAR T 2.0)

    Prikaži ovu nit
    Poništi
  14. 19. sij

    True platforms are coming to bio, built on computational/engineering foundations that give meaningful tech-enabled knowledge or capability edge. One example: AI. Excitement can crossover into hype, but AI is helping take some guesswork out of clinical diagnosis + drug discovery.

    Prikaži ovu nit
    Poništi
  15. 19. sij

    Traditional biotech VCs created a generation of transformational biotech companies. But a new breed of bio founder wants to take the reins: they’re domain experts; many are best positioned to drive their own innovations forward as CEO. Bio VCs need to catalyze rather than create.

    Prikaži ovu nit
    Poništi
  16. 19. sij

    Reflecting on , I’m struck by a sea change in healthcare. Everything is on the table: questioning old assumptions, sparking new debates. As traditional tech + biotech merge into “bio”, we need to revisit some outdated mindsets for this new world👇

    Prikaži ovu nit
    Poništi
  17. 18. sij

    Good on you, . Thank you, Pres Ron Daniels. And this undoubtedly wouldn’t be possible without —his incredible acts of generosity have transformed the lives of generations of JHU students. Johns Hopkins had an indelible impact on my life and career.

    Poništi
  18. 17. sij
    Poništi
  19. 16. sij

    “If you lived here you’d be a home by now.”

    Poništi
  20. 15. sij

    If EQRx achieved even a fraction of their goal, it would still have an incredible impact on the industry, and most importantly, help patients.

    Prikaži ovu nit
    Poništi
  21. 15. sij

    In fairness, it’s a thoughtful critique. But a bet is a cheap stunt. Anyone could bet every company on the planet that they won’t hit their 10-yr projections and would win every single time.

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·